Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Kluge AF, Patane MA, Van Drie JH, Wang C, McElligott D, Kesicki EA, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2018 Jun;558(7710):E1. doi: 10.1038/s41586-018-0111-5.

PMID:
29769713
2.

Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.

Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam B, Ernst JT, Han Q, Goel VK, Han EZR, Huang V, Hung INJ, Jemison A, Jessen KA, Molter J, Murphy D, Neal M, Parker GS, Shaghafi M, Sperry S, Staunton J, Stumpf CR, Thompson PA, Tran C, Webber SE, Wegerski CJ, Zheng H, Webster KR.

J Med Chem. 2018 Apr 26;61(8):3516-3540. doi: 10.1021/acs.jmedchem.7b01795. Epub 2018 Mar 29.

PMID:
29526098
3.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2017 Oct 5;550(7674):128-132. doi: 10.1038/nature24028. Epub 2017 Sep 27. Erratum in: Nature. 2018 May 16;:.

4.

Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

He Y, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, Shaw B, The J, Lima-Fernandes E, Szewczyk MM, Cheng D, Klinge KL, Li HQ, Pliushchev M, Algire MA, Maag D, Guo J, Dietrich J, Panchal SC, Petros AM, Sweis RF, Torrent M, Bigelow LJ, Senisterra G, Li F, Kennedy S, Wu Q, Osterling DJ, Lindley DJ, Gao W, Galasinski S, Barsyte-Lovejoy D, Vedadi M, Buchanan FG, Arrowsmith CH, Chiang GG, Sun C, Pappano WN.

Nat Chem Biol. 2017 Jul 18;13(8):922. doi: 10.1038/nchembio0817-922b. No abstract available.

PMID:
28853738
5.

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Curtin ML, Heyman HR, Clark RF, Sorensen BK, Doherty GA, Hansen TM, Frey RR, Sarris KA, Aguirre AL, Shrestha A, Tu N, Woller K, Pliushchev MA, Sweis RF, Cheng M, Wilsbacher JL, Kovar PJ, Guo J, Cheng D, Longenecker KL, Raich D, Korepanova AV, Soni NB, Algire MA, Richardson PL, Marin VL, Badagnani I, Vasudevan A, Buchanan FG, Maag D, Chiang GG, Tse C, Michaelides MR.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3317-3325. doi: 10.1016/j.bmcl.2017.06.018. Epub 2017 Jun 14.

PMID:
28610984
6.

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.

Wilsbacher JL, Cheng M, Cheng D, Trammell SAJ, Shi Y, Guo J, Koeniger SL, Kovar PJ, He Y, Selvaraju S, Heyman HR, Sorensen BK, Clark RF, Hansen TM, Longenecker KL, Raich D, Korepanova AV, Cepa S, Towne DL, Abraham VC, Tang H, Richardson PL, McLoughlin SM, Badagnani I, Curtin ML, Michaelides MR, Maag D, Buchanan FG, Chiang GG, Gao W, Rosenberg SH, Brenner C, Tse C.

Mol Cancer Ther. 2017 Jul;16(7):1236-1245. doi: 10.1158/1535-7163.MCT-16-0819. Epub 2017 May 3.

7.

SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.

Curtin ML, Pliushchev MA, Li HQ, Torrent M, Dietrich JD, Jakob CG, Zhu H, Zhao H, Wang Y, Ji Z, Clark RF, Sarris KA, Selvaraju S, Shaw B, Algire MA, He Y, Richardson PL, Sweis RF, Sun C, Chiang GG, Michaelides MR.

Bioorg Med Chem Lett. 2017 Apr 1;27(7):1576-1583. doi: 10.1016/j.bmcl.2017.02.030. Epub 2017 Feb 20.

PMID:
28254486
8.

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

He Y, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, Shaw B, The J, Lima-Fernandes E, Szewczyk MM, Cheng D, Klinge KL, Li HQ, Pliushchev M, Algire MA, Maag D, Guo J, Dietrich J, Panchal SC, Petros AM, Sweis RF, Torrent M, Bigelow LJ, Senisterra G, Li F, Kennedy S, Wu Q, Osterling DJ, Lindley DJ, Gao W, Galasinski S, Barsyte-Lovejoy D, Vedadi M, Buchanan FG, Arrowsmith CH, Chiang GG, Sun C, Pappano WN.

Nat Chem Biol. 2017 Apr;13(4):389-395. doi: 10.1038/nchembio.2306. Epub 2017 Jan 30. Erratum in: Nat Chem Biol. 2017 Jul 18;13(8):922.

PMID:
28135237
9.

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity.

Bromberg KD, Mitchell TR, Upadhyay AK, Jakob CG, Jhala MA, Comess KM, Lasko LM, Li C, Tuzon CT, Dai Y, Li F, Eram MS, Nuber A, Soni NB, Manaves V, Algire MA, Sweis RF, Torrent M, Schotta G, Sun C, Michaelides MR, Shoemaker AR, Arrowsmith CH, Brown PJ, Santhakumar V, Martin A, Rice JC, Chiang GG, Vedadi M, Barsyte-Lovejoy D, Pappano WN.

Nat Chem Biol. 2017 Mar;13(3):317-324. doi: 10.1038/nchembio.2282. Epub 2017 Jan 23.

PMID:
28114273
10.

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.

Pappano WN, Guo J, He Y, Ferguson D, Jagadeeswaran S, Osterling DJ, Gao W, Spence JK, Pliushchev M, Sweis RF, Buchanan FG, Michaelides MR, Shoemaker AR, Tse C, Chiang GG.

PLoS One. 2015 Jul 6;10(7):e0131716. doi: 10.1371/journal.pone.0131716. eCollection 2015.

11.

Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.

Sweis RF, Wang Z, Algire M, Arrowsmith CH, Brown PJ, Chiang GG, Guo J, Jakob CG, Kennedy S, Li F, Maag D, Shaw B, Soni NB, Vedadi M, Pappano WN.

ACS Med Chem Lett. 2015 Apr 29;6(6):695-700. doi: 10.1021/acsmedchemlett.5b00124. eCollection 2015 Jun 11.

12.

Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.

Sweis RF, Pliushchev M, Brown PJ, Guo J, Li F, Maag D, Petros AM, Soni NB, Tse C, Vedadi M, Michaelides MR, Chiang GG, Pappano WN.

ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. doi: 10.1021/ml400496h. eCollection 2014 Feb 13.

13.

Directed evolution of mammalian anti-apoptosis proteins by somatic hypermutation.

Majors BS, Chiang GG, Pederson NE, Betenbaugh MJ.

Protein Eng Des Sel. 2012 Jan;25(1):27-38. doi: 10.1093/protein/gzr052. Epub 2011 Dec 9.

14.

Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect.

Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW.

J Biol Chem. 2011 Dec 9;286(49):42626-34. doi: 10.1074/jbc.M111.282046. Epub 2011 Oct 13.

15.

Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.

Feng Y, Barile E, De SK, Stebbins JL, Cortez A, Aza-Blanc P, Villanueva J, Heryln M, Krajewski S, Pellecchia M, Ronai ZA, Chiang GG.

Pigment Cell Melanoma Res. 2011 Aug;24(4):703-13. doi: 10.1111/j.1755-148X.2011.00867.x. Epub 2011 Jun 6.

16.

Control of mTORC1 signaling by the Opitz syndrome protein MID1.

Liu E, Knutzen CA, Krauss S, Schweiger S, Chiang GG.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8680-5. doi: 10.1073/pnas.1100131108. Epub 2011 May 9.

17.

Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.

Kladney RD, Cardiff RD, Kwiatkowski DJ, Chiang GG, Weber JD, Arbeit JM, Lu ZH.

Cancer Res. 2010 Nov 1;70(21):8937-47. doi: 10.1158/0008-5472.CAN-10-1646. Epub 2010 Oct 12.

18.

Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis.

Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM.

Cancer Res. 2010 Apr 15;70(8):3287-98. doi: 10.1158/0008-5472.CAN-09-3467. Epub 2010 Apr 13.

19.

Divergent S phase checkpoint activation arising from prereplicative complex deficiency controls cell survival.

Lau E, Chiang GG, Abraham RT, Jiang W.

Mol Biol Cell. 2009 Sep;20(17):3953-64. doi: 10.1091/mbc.E09-01-0022. Epub 2009 Jul 8.

20.

REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase.

Katiyar S, Liu E, Knutzen CA, Lang ES, Lombardo CR, Sankar S, Toth JI, Petroski MD, Ronai Z, Chiang GG.

EMBO Rep. 2009 Aug;10(8):866-72. doi: 10.1038/embor.2009.93. Epub 2009 Jun 26.

21.

Mcl-1 overexpression leads to higher viabilities and increased production of humanized monoclonal antibody in Chinese hamster ovary cells.

Majors BS, Betenbaugh MJ, Pederson NE, Chiang GG.

Biotechnol Prog. 2009 Jul-Aug;25(4):1161-8. doi: 10.1002/btpr.192.

PMID:
19551877
22.

Protein and genome evolution in Mammalian cells for biotechnology applications.

Majors BS, Chiang GG, Betenbaugh MJ.

Mol Biotechnol. 2009 Jun;42(2):216-23. doi: 10.1007/s12033-009-9156-x. Epub 2009 Apr 15. Review.

PMID:
19367473
23.

The role of Dbf4/Drf1-dependent kinase Cdc7 in DNA-damage checkpoint control.

Tsuji T, Lau E, Chiang GG, Jiang W.

Mol Cell. 2008 Dec 26;32(6):862-9. doi: 10.1016/j.molcel.2008.12.005.

24.

E2F-1 overexpression increases viable cell density in batch cultures of Chinese hamster ovary cells.

Majors BS, Arden N, Oyler GA, Chiang GG, Pederson NE, Betenbaugh MJ.

J Biotechnol. 2008 Nov 25;138(3-4):103-6. doi: 10.1016/j.jbiotec.2008.08.003. Epub 2008 Aug 20.

PMID:
18778741
25.

Enhancement of transient gene expression and culture viability using Chinese hamster ovary cells overexpressing Bcl-x(L).

Majors BS, Betenbaugh MJ, Pederson NE, Chiang GG.

Biotechnol Bioeng. 2008 Oct 15;101(3):567-78. doi: 10.1002/bit.21917.

PMID:
18727128
26.

Targeting the mTOR signaling network in cancer.

Chiang GG, Abraham RT.

Trends Mol Med. 2007 Oct;13(10):433-42. Epub 2007 Oct 1. Review.

PMID:
17905659
27.

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.

Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT.

Mol Cancer Ther. 2007 Sep;6(9):2505-14. Epub 2007 Aug 31.

28.

Links between metabolism and apoptosis in mammalian cells: applications for anti-apoptosis engineering.

Majors BS, Betenbaugh MJ, Chiang GG.

Metab Eng. 2007 Jul;9(4):317-26. Epub 2007 May 23. Review.

PMID:
17611135
29.

The FRB domain of mTOR: NMR solution structure and inhibitor design.

Leone M, Crowell KJ, Chen J, Jung D, Chiang GG, Sareth S, Abraham RT, Pellecchia M.

Biochemistry. 2006 Aug 29;45(34):10294-302.

PMID:
16922504
30.

Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway.

Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, Abraham RT.

Mol Cell. 2005 Sep 2;19(5):607-18.

31.
32.

Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.

Chiang GG, Abraham RT.

J Biol Chem. 2005 Jul 8;280(27):25485-90. Epub 2005 May 16.

33.

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.

Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K, Abraham RT, Shokat KM.

Bioorg Med Chem. 2004 Sep 1;12(17):4749-59.

PMID:
15358300
34.

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.

Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G.

Org Biomol Chem. 2004 Jul 7;2(13):1911-20. Epub 2004 Jun 14.

PMID:
15227545
35.
36.

Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.

Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT.

Cancer Res. 2003 Dec 1;63(23):8451-60.

37.

A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity.

Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, MacLean A, Sisk W, Thill G.

J Immunol Methods. 2003 Jun 1;277(1-2):141-55.

PMID:
12799047
38.

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT.

Mol Cell Biol. 2002 Oct;22(20):7004-14.

39.
40.
41.

Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.

Chiang GG, Rubin HL, Cherington V, Wang T, Sobolewski J, McGrath CA, Gaffney A, Emami S, Sarver N, Levine PH, Greenberger JS, Hurwitz DR.

Hum Gene Ther. 1999 Jan 1;10(1):61-76.

PMID:
10022531
42.

Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion.

Cherington V, Chiang GG, McGrath CA, Gaffney A, Galanopoulos T, Merrill W, Bizinkauskas CB, Hansen M, Sobolewski J, Levine PH, Greenberger JS, Hurwitz DR.

Hum Gene Ther. 1998 Jul 1;9(10):1397-407.

PMID:
9681411
43.

Tyrosine phosphorylation of RNA polymerase II carboxyl-terminal domain by the Abl-related gene product.

Baskaran R, Chiang GG, Mysliwiec T, Kruh GD, Wang JY.

J Biol Chem. 1997 Jul 25;272(30):18905-9.

44.

Enhanced growth of canine bone marrow stromal cell cultures in the presence of acidic fibroblast growth factor and heparin.

Emami S, Merrill W, Cherington V, Chiang GG, Kirchgesser M, Appel JM, Hansen M, Levine PH, Greenberger JS, Hurwitz DR.

In Vitro Cell Dev Biol Anim. 1997 Jul-Aug;33(7):503-11.

PMID:
9282310
45.
46.

Plasmids from two morphologically distinct cyanobacterial strains share a novel replication origin.

Schaefer MR, Chiang GG, Cobley JG, Grossman AR.

J Bacteriol. 1993 Sep;175(17):5701-5.

47.

The phycobilisome, a light-harvesting complex responsive to environmental conditions.

Grossman AR, Schaefer MR, Chiang GG, Collier JL.

Microbiol Rev. 1993 Sep;57(3):725-49. Review.

48.

Environmental effects on the light-harvesting complex of cyanobacteria.

Grossman AR, Schaefer MR, Chiang GG, Collier JL.

J Bacteriol. 1993 Feb;175(3):575-82. Review. No abstract available.

49.

Complementation of a red-light-indifferent cyanobacterial mutant.

Chiang GG, Schaefer MR, Grossman AR.

Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9415-9.

Supplemental Content

Loading ...
Support Center